These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38958260)

  • 21. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience.
    Scarano SM; Bruzzese E; Poeta M; Del Bene M; Guarino A; Lo Vecchio A
    Antibiotics (Basel); 2024 Apr; 13(4):. PubMed ID: 38667003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
    Leuthner KD; Buechler KA; Kogan D; Saguros A; Lee HS
    Ther Clin Risk Manag; 2016; 12():931-40. PubMed ID: 27354809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
    Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
    Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
    Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dalbavancin in clinical practice in Spain: a 2 year retrospective study.
    Morata L; Aguado JM; Salavert M; Pasquau J; Míguez E; Muñoz P; Rosselló I; Almirante B
    JAC Antimicrob Resist; 2022 Dec; 4(6):dlac120. PubMed ID: 36570687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.
    Juul JJ; Mullins CF; Peppard WJ; Huang AM
    Ther Clin Risk Manag; 2016; 12():225-32. PubMed ID: 26937194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients.
    Pizzuti AG; Murray EY; Wagner JL; Gaul DA; Bland CM; Jones BM
    Infect Dis Ther; 2020 Dec; 9(4):1043-1053. PubMed ID: 33083894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
    Soriano A; Rossolini GM; Pea F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
    Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic antibiotic suppressive therapy with dalbavancin: a case series.
    Pallotto C; Tommasi A; Albagini M; Genga G; Svizzeretto E; Gidari A; Tordi S; Francisci D
    J Chemother; 2024 May; ():1-5. PubMed ID: 38712995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
    Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
    Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.
    Morata L; Cobo J; Fernández-Sampedro M; Guisado Vasco P; Ruano E; Lora-Tamayo J; Sánchez Somolinos M; González Ruano P; Rico Nieto A; Arnaiz A; Estébanez Muñoz M; Jiménez-Mejías ME; Lozano Serrano AB; Múñez E; Rodriguez-Pardo D; Argelich R; Arroyo A; Barbero JM; Cuadra F; Del Arco A; Del Toro MD; Guio L; Jimenez-Beatty D; Lois N; Martin O; Martínez Alvarez RM; Martinez-Marcos FJ; Porras L; Ramírez M; Vergas García J; Soriano A
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
    Gonzalez PL; Rappo U; Mas Casullo V; Akinapelli K; McGregor JS; Nelson J; Nowak M; Puttagunta S; Dunne MW
    Infect Dis Ther; 2021 Mar; 10(1):471-481. PubMed ID: 33515414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
    Arrieta-Loitegui M; Caro-Teller JM; Ortiz-Pérez S; López-Medrano F; San Juan-Garrido R; Ferrari-Piquero JM
    Eur J Hosp Pharm; 2022 Jan; 29(1):55-58. PubMed ID: 33020060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dalbavancin: a new lipoglycopeptide antibiotic.
    Bailey J; Summers KM
    Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of long-acting antibiotics in the clinical practice: a narrative review.
    Micheli G; Chiuchiarelli M; Taccari F; Fantoni M
    Infez Med; 2023; 31(4):449-465. PubMed ID: 38075413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications.
    Bassetti M; Labate L; Vena A; Giacobbe DR
    Curr Opin Infect Dis; 2021 Apr; 34(2):96-108. PubMed ID: 33405480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.